Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.
Olivia Pagani, MD
Advertisement
Articles by Olivia Pagani, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
2
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
3
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
4
124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
5